sTREM-1和hs-CRP对COPD急性加重期患者的初始治疗效果评价

Effect evaluation of sTREM-1 and hs-CRP during initial treatment for patients with chronic obstructive pulmonary disease in acute exacerbation period

目的:探究可溶性髓系细胞触发受体-1(sTREM-1)及超敏C反应蛋白(hs-CRP)对慢性阻塞性肺疾病急性加重期(AECOPD)患者的初始抗生素治疗效果的评估价值。方法:选取佳木斯大学附属第一医院呼吸科内科住院的48例AECOPD病人,测定病人入院第1天、第4天血清sTREM-1和hs-CRP水平,并比较入院第1天时和入院第4天的sTREM-1和hs-CRP水平的变化和区别。结果:sTREM-1和hs-CRP治疗后显著下降(P<0.05)。结论:随着应用抗生素治疗有效,AECOPD患者血清sTREM-1、hs-CRP降低,故推测二者联测可能对加重期病人抗菌素的初始治疗疗效评估有一定的临床价值。

Objective:To evaluate the effect of sTREM-1 and hs-CRP on predicting initial treatment response in chronic obstructive pulmonary disease in acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods:48 cases of patients with AECOPD were selected,and sTREM-1 and hs-CRP level in1 d,4 d were determined,and compared the level changes and difference in 1 d,4 d.Results:sTREM-1 and hs-CRP were significantly reduced after treatment(P<0.05).Conclusion:With effective antibiotic treatment,sTREM-1 and hs-CRP are reduced.The united measurement may have effect on predicting initial treatment response in patients with AECOPD.